Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 175M | 8.7% |
| Gross Profit | 43M | 8.7% |
| Cost of Revenue | 132M | 8.7% |
| Operating expense | 214M | 13.3% |
| Net Income | -26M | 62.3% |
| EBITDA | -39M | 40.8% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 1.32B | 0.3% |
| Total Liabilities | 180M | 2.1% |
| Total Equity | 1.14B | 0% |
| Shares Outstanding | 106M | 0.4% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -27M | 4993.9% |
| Cash from investing | -209M | 2793.8% |
| Cash from financing | 6.7M | 98.8% |
EPS
Financial Highlights for Intra-Cellular Therapies in Q3 '24
Intra-Cellular Therapies reported a revenue of 175M, which is a 8.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 43M, marking a 8.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 132M, a 8.7% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 214M, showing a 13.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -26M, showing a -62.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -39M, showing a -40.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Intra-Cellular Therapies faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
